287 related articles for article (PubMed ID: 24053777)
1. The transcriptional programme of the androgen receptor (AR) in prostate cancer.
Lamb AD; Massie CE; Neal DE
BJU Int; 2014 Mar; 113(3):358-66. PubMed ID: 24053777
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
3. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
4. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
5. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
Mitsiades N
Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mashima T; Okabe S; Seimiya H
Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor antagonists for prostate cancer therapy.
Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
[TBL] [Abstract][Full Text] [Related]
9. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
[TBL] [Abstract][Full Text] [Related]
10. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer.
Sato M; Johnson M; Zhang L; Gambhir SS; Carey M; Wu L
Clin Cancer Res; 2005 May; 11(10):3743-9. PubMed ID: 15897571
[TBL] [Abstract][Full Text] [Related]
11. [Molecular biology of castration-resistant prostate cancer].
Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
[TBL] [Abstract][Full Text] [Related]
12. Strategies for targeting the androgen receptor axis in prostate cancer.
Carver BS
Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
[TBL] [Abstract][Full Text] [Related]
13. Sequencing the transcriptional network of androgen receptor in prostate cancer.
Chng KR; Cheung E
Cancer Lett; 2013 Nov; 340(2):254-60. PubMed ID: 23196061
[TBL] [Abstract][Full Text] [Related]
14. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
Mellado B; Marin Aguilera M; Pereira MV
Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional Regulation in Prostate Cancer.
Labbé DP; Brown M
Cold Spring Harb Perspect Med; 2018 Nov; 8(11):. PubMed ID: 29530947
[TBL] [Abstract][Full Text] [Related]
16. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
17. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
18. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
19. Collocation of androgen receptor gene mutations in prostate cancer.
Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
[TBL] [Abstract][Full Text] [Related]
20. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.
Shiota M; Yokomizo A; Naito S
J Mol Endocrinol; 2011 Aug; 47(1):R25-41. PubMed ID: 21504942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
